FDA recall record

Brassica Pharma Pvt CVS Health Lubricant Eye Ointment recall — FDA D-0353-2024

Lack of Assurance of Sterility

Class IIclassification
D-0353-2024official record ID
Mar 6, 2024report date

Recall record at a glance

Official recordD-0353-2024
CategoryDrug Recalls
ClassificationClass II
FDA record statusOngoing
Recalling firmBrassica Pharma Pvt Ltd
Report dateMar 6, 2024
Recall initiation dateJan 30, 2024
Quantity159,334 units
LocationThane, India

Official product description

CVS Health Lubricant Eye Ointment (Mineral oil 31.9% Emollient, White petrolatum 57.7% Emollient), Packaged in in 3.5 gram tubes, Distributed by: CVS Pharmacy, Inc. One CVS Drive Woonsocket, RI 02895, NDC 76168-707-35, UPC 050428634141

Why the product was recalled

Lack of Assurance of Sterility

Distribution information

Nationwide within the United States

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.